Chikungunya Virus Antibody (6A11) [Janelia Fluor® 549]

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-53111JF549

Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Virus

Applications

Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Western Blot

Label

Janelia Fluor 549

Antibody Source

Monoclonal Mouse IgG2B Clone # 6A11

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

View all Chikungunya Virus Antibodies »

Product Specifications

Immunogen

Live Chikungunya Virus

Epitope

N218 epitope on E2 protein of Chikungunya Virus

Clonality

Monoclonal

Host

Mouse

Isotype

IgG2B

Applications for Chikungunya Virus Antibody (6A11) [Janelia Fluor® 549]

Application
Recommended Usage

Flow Cytometry

Optimal dilutions of this antibody should be experimentally determined.

Immunocytochemistry/ Immunofluorescence

Optimal dilutions of this antibody should be experimentally determined.

Western Blot

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A purified

Formulation

50mM Sodium Borate

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark.

Background: Chikungunya Virus

Chikungunya virus (CHIKV) belongs to the family of alphaviruses and is transmitted by Aedes mosquitoes resulting in infection characterized by symptoms including arthritis-like joint pain and inflammation, fever, rash, and headache (1-3). The CHIKV genome consists of an 11.8 kilobase (kb) positive-sense, single-stranded RNA virus that has two open reading frames (ORFs) (1-3). The first ORF at the 5' end encodes a 2472 amino acid (aa) nonstructural polyprotein and the ORF at the 3' end encodes a 1244 aa structural polyprotein (1-3). The polyproteins generate four nonstructural proteins (nsP1-4) and five structural proteins: capsid (C), envelope E1, E2, E3, and 6K (1-3). The nonstructural proteins comprise CHIKV's RNA replicase (1,2). Structurally, CHIKV has a diameter of ~65 nm and the virion is formed by an icosahedral nucleocapsid shell encapsulating genomic RNA and surrounded by a lipid bilayer envelope (2,3).

Although analysis suggests CHIKV originated in Africa over 500 years ago, first infections weren't reported until the 1950s (1-3). CHIKV has evolved three distinct genotypes, or strains, based on location, termed West African (WA), East/Central/Southern African (ECSA), and Asian (2-3). The WA strain has been most closely associated with enzootic transmission whereas the ECSA strain contributes more to urban epidemics (2). Nonhuman primates are the primary reservoir for the viral host with transmission occurring via mosquitos biting and infecting humans (1-3). Upon acute infection, the virus replicates in cells including fibroblasts and macrophages resulting in innate immune response in infected tissues characterized by infiltrating cells like macrophages, monocytes, natural killer (NK) cells, and lymphocytes (2,3). Infection results in increased production of proinflammatory cytokines such as interferon alpha (IFN-alpha) and interleukin 6 (IL-6), chemokines, and growth factors (2,3). Physical manifestations of infection are high fever, polyarthralgia, headache, arthritis, and rash (1-3). CHIKV symptoms can be confused with other infections like those from dengue fever and Zika virus (1-3). There are no specific antivirals or vaccines for CHIKV, but rather symptoms are treated with antipyretics and non-steroidal anti-inflammatory drugs (NSAIDs) (2,3). While in vitro culture models and in vivo rodent and non-human primate models have been used to study CHIKV pathogenesis and advance our knowledge of the disease, the specific cellular mechanisms are not fully understood (3).

References

1. Vu DM, Jungkind D, Angelle Desiree LaBeaud. Chikungunya Virus. Clin Lab Med. 2017;37(2):371-382. https://doi.org/10.1016/j.cll.2017.01.008

2. Silva LA, Dermody TS. Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies. J Clin Invest. 2017;127(3):737-749. https://doi.org/10.1172/JCI84417

3. Ganesan VK, Duan B, Reid SP. Chikungunya Virus: Pathophysiology, Mechanism, and Modeling. Viruses. 2017;9(12):368. Published 2017 Dec 1. https://doi.org/10.3390/v9120368

Alternate Names

Chikungunya

Additional Chikungunya Virus Products

Product Documents for Chikungunya Virus Antibody (6A11) [Janelia Fluor® 549]

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for Chikungunya Virus Antibody (6A11) [Janelia Fluor® 549]

Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.